Evelo Biosciences, Inc.
https://evelobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Evelo Biosciences, Inc.
Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds
Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.
New Modalities Help Chinese Biotechs Win Investors’ Attention
Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.
Finance Watch: Biotech Stocks Stabilize At The End Of A Rocky Week
Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Epiva Biosciences, Evelo Therapeutics, Flagship Ventures, Flagship VentureLabs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice